M Pharmaceutical, a Canadian developer of technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, has appointed Matthew Lehman as President and Chief Executive, effective from 1 September.
Lehman has more than 15 years of executive level experience in the development of therapeutics.
Martin Mintchev, the leading inventor of the company's technologies and its co-founder, will move from CEO to Chief Scientific Officer.
'I am pleased to join M Pharmaceutical at this crucial time as we plan for the clinical development and global commercialisation of our products,' said Lehman. 'Dr Mintchev and his team have set a great foundation with innovative technologies and strong patent protection. I look forward to working with Dr Mintchev to expedite development of the Trimeo Weight Loss Capsules, Trimtec Gastric Neurotimulation System, and eMosquito Wearable Blood Monitor.'
Lehman will be based in the Cincinnati, Ohio area, where the company expects to establish its US operating presence and focus on its most important global market.
Most recently, Lehman was CEO of Prima Biomed, a developer of cancer immunotherapies.
As of 1 September, Lehman will also be appointed to the company's Board of Directors.
